**
A recent analysis has revealed that the weight-loss medication semaglutide, commercially available as Ozempic for diabetes and Wegovy for obesity, could potentially be produced for as little as $3 a month. This significant reduction in cost could open the door for millions across 160 nations to access vital treatment, especially as patents on the drug begin to expire.
A Global Health Crisis
Currently, over a billion individuals around the globe are affected by obesity, a figure that is rapidly ascending, particularly in low-income countries where dietary patterns are shifting towards more westernised and sedentary lifestyles. The World Health Organization (WHO) recognised semaglutide as an essential medicine in September of last year but cautioned that its high price remains a substantial barrier to access for those in dire need.
Research emerging from Liverpool University indicates that semaglutide could be manufactured at a fraction of its current retail price. Specifically, the injectable form of the drug could be produced for $3 (approximately £2.35) per month, while newer pill formulations might cost around $16 monthly. Dr Andrew Hill, a pharmacologist involved in the study, highlighted that these lowered prices could significantly enhance global access to this crucial medication.
The Patent Landscape
The research underscores an impending shift in the pharmaceutical landscape, with core patents on semaglutide set to expire in ten countries, including Brazil, China, India, South Africa, and Turkey, come March 21 this year. This development paves the way for generic alternatives to enter the market, potentially driving prices even lower. The study further identified an additional 150 nations, primarily in Africa, where no patents for semaglutide have been filed, presenting a unique opportunity for widespread availability. Collectively, these 160 nations account for 69% of individuals diagnosed with type 2 diabetes and 84% of those living with obesity.
Prof François Venter from Witwatersrand University in Johannesburg remarked on the potential of this breakthrough. Drawing parallels with other life-saving medications for HIV, tuberculosis, and malaria that have become accessible in low and middle-income countries, he expressed optimism that a similar success story could unfold for semaglutide.
Necessary Considerations for Implementation
While the prospect of cheaper access to semaglutide is promising, experts caution that effective treatment of obesity and diabetes extends beyond merely providing affordable medications. Dr Nomathemba Chandiwana, chief scientific officer at the Desmond Tutu Health Foundation, emphasised that structural factors such as food insecurity, poverty, and urbanisation need to be addressed alongside improved access to medication. She noted that around 27% of adults globally qualify for treatments like semaglutide, with the majority residing in low and middle-income contexts where access remains severely restricted.
The pressing question, as highlighted by Chandiwana, is how health systems will integrate these drugs into comprehensive care strategies for obesity and diabetes, ensuring that they complement broader health initiatives.
The Scale of the Challenge
Obesity is not merely a standalone issue; it is intricately linked with a range of serious health conditions, including heart disease, diabetes, strokes, and certain cancers. The consequences are stark, with 3.7 million deaths each year attributed to complications arising from excess weight. As the prevalence of diabetes has surged from 200 million in 1990 to a staggering 830 million in 2022, particularly in lower-income countries, the urgency for effective interventions is undeniable.
Semaglutide has been available in the United States since its approval in 2017, where it costs around $200 per month, and about £120 in the UK. However, patents in these regions will remain effective for another five years, which poses challenges for immediate price reductions and access.
Why it Matters
The findings of this research hold profound implications for global health equity. If semaglutide can be produced affordably, millions of individuals suffering from obesity and diabetes in low-income countries could finally gain access to a life-changing treatment. However, the success of this initiative will depend on not just the availability of the drug, but also on comprehensive strategies that address the root causes of these chronic conditions. As nations strive to combat rising obesity and diabetes rates, the potential for improved health outcomes hinges on a coordinated effort that combines access to affordable medications with structural changes aimed at fostering healthier lifestyles.